{"name":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","slug":"jiangsu-chia-tai-fenghai-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"FHND9041","genericName":"FHND9041","slug":"fhnd9041","indication":"Unknown","status":"phase_3"},{"name":"FHND5071","genericName":"FHND5071","slug":"fhnd5071","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"FHND9041","genericName":"FHND9041","slug":"fhnd9041","phase":"phase_3","mechanism":"FHND9041 is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"FHND5071","genericName":"FHND5071","slug":"fhnd5071","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQRGR6R0gwVzYzUU5JVFdEbFlGb2gtZ3NEWW5aS2NXcWwzVFVhRnV2NWoweFYteUhrVk5PY3ZnOVJZeDVLMUd5NDBvV3llVDRlbGV0M1AxUE9pWWF6X0pnVnVRbDE4RDdxd3FmZGlnalVnQWViMkRUWk1SbWF6RjN0Q0pWc01MeWU2Wjc5VGdHOUY?oc=5","date":"2026-03-05","type":"trial","source":"endpoints.news","summary":"Updated: Sanofi licenses Sino Biopharm's 'breakout star' transplant drug for $135M upfront - endpoints.news","headline":"Updated: Sanofi licenses Sino Biopharm's 'breakout star' transplant drug for $135M upfront","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOUVpfcDNiUGZnelozQmZqTjd6aGxPZXBKa2s0cHVQa055WUthRGJab2pzTVZqVjNhLUxhQUJocmZLQVF6aVNtNXJJR1pXeWRhTEp1NkhqYVpXenBMMkViN3pYd3E5OEJ0SEpXM3ktaUFYZE9Wd3YyX0llSGhKNmhCX3phZ2NmUWpBYVNYZjQ5OGhQLWh5Y0RsQnFJUnM0enZFWTlTYkhUS0NLendHclJvRERn?oc=5","date":"2026-03-04","type":"deal","source":"Fierce Pharma","summary":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset - Fierce Pharma","headline":"Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQTWVjNkZNdG52TFpBXzZuVXZHT2VBNlhmS2RZUWtEYU5rT3dnSnpCY2k5WUc2M2Zyd044ang4amxnNzJRUWY2SHFGcFNBeFZvb0dSZWpvY0FxZjJEOUZzVFN6RDZLUEQtbHdORHZ5OWkyZ211NlQ3U2tIVGtuWndOazZwYjlodXhETTU0?oc=5","date":"2026-02-06","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: AstraZeneca, SanegeneBio, Sanofi and more - Medical Marketing and Media","headline":"Rx Rundown: AstraZeneca, SanegeneBio, Sanofi and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPZ0NOX1dOVnk1YnRoZGZNWjRaMmxFSEx3VzlzVWN4SUc1dkRLR19uSjU5ZWxwdjR3U3hEeW1fVGxwS3Fwb1ZtUVB0Nnp6WEZKNFU4ZTJaNDdFUDNvLXNuX2dGVEhtODVPU0hVVWRYTzhQbEFMUl8wVlhOUEZfb1VCaTAwa1BlQy11dlV1OVBVUkQtak9ldDBheXpCYw?oc=5","date":"2026-01-29","type":"deal","source":"The Pharma Letter","summary":"Formation Bio licenses miR-124 activator from China - The Pharma Letter","headline":"Formation Bio licenses miR-124 activator from China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPTmR3WE1PZ1FPVWRHaXJ2X3VxVlFYNnItTVZyaURZUUFZSjlkYlowMFp5T1RwLU5RbUFmalg5Nm1BNjNueFIzT0RkMVhIMm9wZTdfRjB1NU1xejR6M0J5TkFZSDlEdmNLSTZBVGthYk5YTnZ0LUJtajd2dkdSWkcyUHBSckFtTWxaWGlCX0xoV01VQV96REl5a1dfM2xQTEFpYlkyVllneXVNMWMxaVBDNXI0MjQ0SkdkWmJSSDNMSFlNS1Y0RTZIcTJ2X0VVLUhueGtGMy1pSy1VMk4xcm1wVHRQaWsybDZNd2M1NUYyVnc3YUN4M1VCYmNCV0FLakxhazBV?oc=5","date":"2025-09-18","type":"pipeline","source":"PR Newswire","summary":"Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development - PR Newswire","headline":"Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQX3Bnd0RBZDg1YmswRDdYMmktZ2pvbEk4V1lzRWNObTNPSkRDNW5kX0ZidU5kZEtMSG9RQVptNkhPRmpzUEpUdjdmdjJXdEJXWkFBQmU2QWd4bldvTnZ2WWdHSl80WVNmdmdTdWlKQjkzX2UwdFNuSUpIcDgxUXd0YXFHS2NYMzQzNm9QRHpYeEVTX3pESkVNN2Q0aURIcl9YTWJvQkdMOA?oc=5","date":"2025-05-16","type":"pipeline","source":"Grand View Research","summary":"China Food For Special Medical Purpose Market Report, 2030 - Grand View Research","headline":"China Food For Special Medical Purpose Market Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOLXMtZlFJTmRmZVZ4YXA5bEdrVHpwTXMzR1VJallzekU0ZXhmUERqOTctUzh1b3FycmM2Ul9hSDYyUF9lSDZheDh6RTc3ZWF6WXlYaWpSZlFtc01IbFRvX3FLeVVqNzFDZmh1elZwR2F2QmR4RUh4WlJFWEQ1X3dGR3J3bTJ4Q2xkOHZXdVFRbE1rVzU3WktXRlE3T1RJUXQ3UUVmcXJMRUswYlYwRmVhM3JWekUxWWp6RnhTLVA3Rm1NSUJlM2pDclpFbThVMDFrOTFzeWUtaDMtVWFsZkdoMUVyVHpEdTVRakVwbFl6SXMwYjZUS3FRR04xYnNWMEk?oc=5","date":"2025-03-24","type":"pipeline","source":"PR Newswire UK","summary":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight - PR Newswire UK","headline":"CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOa3J3eUtwSVJPUklOTUNuMHVEZ2JzNFh2N3lKRG5Ra2RzT1pfd1p0VEd0WHQyandqZlk0UnhzM0hJNkM5djM3ajA4azBFR19od1V1dFRfRzc0NjFSeHN6ZDdmSUF1RVpHZWtGekNPZjVoSDhYM3g2aEhRdFVDRGRzaWRGWm5BeU9QSVFZeE9aRW94emJJYUxLQ0lTRWlUZHc5bFJ6TlB4aFh3cmhmUnE1a0pQUDJEM2FqRld5c19qWnZfZXlPX0ZGNW0ycm5BeUtlN25VMEw3R0F5cUlrbEJYX0hFSTNJSDlWOEJPOVJ3MDhkdTBTR0pKZTJYaXRKSEhkOWlaWTR4QkMwLVYxMzd3amFuenNaLUdsSjF5cUdPYVpBZW9MZk1jazJQUmZNdw?oc=5","date":"2024-11-12","type":"pipeline","source":"PR Newswire","summary":"Formation Bio collaborates with Sanofi and OpenAI to Introduce Muse, a first of its kind AI tool to accelerate patient recruitment in drug development - PR Newswire","headline":"Formation Bio collaborates with Sanofi and OpenAI to Introduce Muse, a first of its kind AI tool to accelerate patient r","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcVQ1TURYQUhPS0tZZ28zc01qSV94ODRja3J5NlI4NEN6Z0NEQ3VQai1nZFk4N3FGcnNXc2NrdzdLcXNkUE13TDJua0VwZHViVmxMdThobksyWlc2M2lnRDZSUFVhelpac1BWaDJ3ZU1WSUppV0dORi1CMHd3M1E3Zm9WbFpIWk9FU1RKYUY3ajhJVE15cXVfMVhXZ0xqbnllVHFJcDNVbDZ5cFhiTHI2V29WSklQSkZBeVQw?oc=5","date":"2023-09-05","type":"pipeline","source":"BioWorld News","summary":"Insilico inches closer to claiming title of first generative AI drug developer - BioWorld News","headline":"Insilico inches closer to claiming title of first generative AI drug developer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNMlJkTVdZcGtqeU5WQ1p2WEs0aUtManBSQ1RKZ1BGOFFoUU9fdlUzZ0FHdzZ2cGhiYk9tWjdqUXBFaTZnakowbkdWWkt1T043X3pCMGk1Z2o3YTR3SlV2Zms4ZzVvV2hBZ3J0RzFvQnpBT0xyb2M5dGFNbFhxaHNsRzlPR2JTNlpnMEppcnJsSFRvQk9vTWtPazVvakgzSWZuSDdaX1RDNVpFUTJiRkxyYUo2Vkk3dGlTeU1GdTlfblBCcmYyQjlWcFp2YXFDbFRScVZxemNXSmVxdjNvd0JBcXBZczAwZDB2WGcwRmxMU1o4YmFjTTE4SzVsUWxkT21XbkxKcWVLWXZvUXJ1bE1GLW9XMWZwQldJZVBTMGdQTTF6UQ?oc=5","date":"2019-10-09","type":"deal","source":"PR Newswire","summary":"CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million - PR Newswire","headline":"CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Wo","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}